The US Regulatory System and COVID-19 Vaccines: The Importance of a Strong and Capable FDA
By Joshua M. Sharfstein, Jesse L. Goodman, and Luciana Borio
Read the full article from Journal of the American Medical Association here.
“For many in public health and medicine, the coronavirus disease 2019 (COVID-19) pandemic in the US has been a frustrating journey from one disappointment to the next: late access to testing, insufficient staff and inadequate funding for contact tracing, jumbled communications, and, at the end of 2020, a chaotic launch of vaccination efforts. But in one area, from the beginning of the pandemic to the present, the US has excelled: facilitating the rapid development of COVID-19 vaccines.”